Dyadic International Reports Q3 2025 Financial Results and Strategic Progress

DYADIC INTERNATIONAL INC

2025-Q3 EPS reported -$0.17 vs consensus -$0.04 ▼ miss (-284.6%)

Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.
Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.
Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.
Secured ERS Genomics CRISPR license to optimize protein production.
Received $1.5 million in milestone payments from Proliant for animal-free serum albumin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.